Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on May 1, 2026 reporting Item 8.01 (Other Events). HEMANGEOL® launched as the only FDA-approved treatment for infantile hemangioma.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- HEMANGEOL® launched as the only FDA-approved treatment for infantile hemangioma
- Pediatric rare-disease launch expands Eton’s commercial product portfolio
- Eton Cares includes $0 co-pay for eligible commercially insured patients
- Expanded patient assistance may improve treatment access and prescription conversion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.